文献速递肝病

疲劳在识别发生疾病进展的NASH合并晚期纤维化患者中的潜在作用

The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-05-06

研究纳入活检确诊的NASH合并桥接纤维化(F3)或代偿性肝硬化(F4)患者,随访至多2年,用CLDQ-NASH疲劳域评分(1-7分,评分越低疲劳越重)量化基线疲劳。F3患者中较低疲劳评分与肝脏相关事件风险升高相关(校正HR 0.85,95%CI 0.74-0.97,P=.02),F4患者中与肝失代偿风险升高相关(校正HR 0.62,95%CI 0.48-0.81,P=.0004)。

要点

  • NASH合并F3患者中15%(n=123)出现肝脏相关事件,F4患者中3.5%(n=31)出现肝失代偿。
  • F3发生肝脏相关事件者基线疲劳评分较低:4.47±1.36 vs 4.83±1.35(P=.0091)。
  • F4发生肝失代偿者基线疲劳评分较低:3.74±1.31 vs 4.59±1.43(P=.0011)。

核心结论

  • 基线疲劳越重与NASH相关晚期纤维化和肝硬化患者不良临床事件风险越高相关。

研究设计与样本

  • 活检确诊NASH合并桥接纤维化(F3)或代偿性肝硬化(F4)的患者随访至多2年,共1679例,其中F3 802例、F4 877例(58±9岁,40%男性,74%为2型糖尿病)。
  • 基线采用CLDQ-NASH疲劳域评分(范围1-7,评分越低表示疲劳越重)量化疲劳,用Cox比例风险模型分析至肝脏相关临床事件的时间。
  • F3的肝脏相关事件定义为进展为组织学肝硬化或肝失代偿,F4定义为肝失代偿。

主要发现

  • 中位随访16个月(四分位距14-18)期间,F3患者15%(n=123)发生肝脏相关事件,F4患者3.5%(n=31)发生肝失代偿。
  • F3患者基线疲劳评分均值4.77±1.36;发生肝脏相关事件者基线评分较低:4.47±1.36 vs 4.83±1.35(P=.0091)。
  • F4患者基线疲劳评分均值4.56±1.44;随访中发生肝失代偿者评分较低:3.74±1.31 vs 4.59±1.43(P=.0011)。
  • 校正混杂因素后,较低疲劳评分与肝脏相关事件或失代偿事件风险的关联仍显著:F3每降低1分校正HR 0.85(95%CI 0.74-0.97,P=.02),F4校正HR 0.62(95%CI 0.48-0.81,P=.0004)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Fatigue is common in patients with advanced liver disease. We investigated fatigue and clinical outcomes among patients with advanced nonalcoholic steatohepatitis (NASH). METHODS: In this study, patients with biopsy confirmed NASH and bridging fibrosis (F3) or compensated cirrhosis (F4) were followed for up to 2 years. The Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) fatigue domain at baseline (range, 1-7; lower score indicating worse fatigue) quantified fatigue. The Cox proportional hazards model was used to study time to liver-related clinical events (progression to histologic cirrhosis or hepatic decompensation in F3, hepatic decompensation in F4). RESULTS: Of the 1679 NASH patients with fibrosis, 802 had F3 and 877 had F4 (58 ± 9 years of age, 40% male, 74% type 2 diabetes). During median follow-up of 16 months (interquartile range, 14-18), 15% (n = 123) of NASH F3 patients experienced liver-related events and 3.5% (n = 31) of NASH F4 patients experienced hepatic decompensation. Mean baseline CLDQ-NASH fatigue score in F3 patients was 4.77 ± 1.36; NASH F3 patients who experienced liver-related events had lower baseline scores: 4.47 ± 1.36 vs 4.83 ± 1.35 (P = .0091). The mean fatigue score in F4 was 4.56 ± 1.44; these scores were lower in patients who decompensated in follow-up: 3.74 ± 1.31 vs 4.59 ± 1.43 (P = .0011). The association of lower fatigue scores and risk of liver-related or decompensation events was significant after adjustment for confounders (adjusted hazard ratio per 1 point in fatigue score in F3, 0.85; 95% confidence interval, 0.74-0.97; P = .02; adjusted hazard ratio in F4, 0.62; 95% confidence interval, 0.48-0.81; P = .0004). CONCLUSION: Worse fatigue at baseline is associated with a higher risk of adverse clinical events in patients with NASH-related advanced fibrosis and cirrhosis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Stepanova M, Myers RP, et al. The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression. Clin Gastroenterol Hepatol. 2022. PMID: 35533993. doi:10.1016/j.cgh.2022.04.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。